Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 4/20 | 0.34 |
| ▸ | GAK | O14976 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14447124 | 0.87 | PTGS2 (0.45) | PTGS2KDM4EKITALDH1A1 | |
| SCHEMBL10188813 | 0.83 | PTGS2 (0.46) | PTGS2MAPTALDH1A1 | |
| SCHEMBL10188923 | 0.82 | PTGS2 (0.45) | PTGS2DHFRKDM4EGAKMAPT | |
| SCHEMBL10188934 | 0.82 | PTGS2 (0.45) | PTGS2DHFRKDM4EKITALDH1A1 | |
| SCHEMBL10188873 | 0.82 | TUBB1 (0.48) | PTGS2KDM4EMAPTALDH1A1GAA | |
| SCHEMBL10189303 | 0.82 | PTGS2 (0.40) | PTGS2DHFRKDM4EGAKALDH1A1 | |
| SCHEMBL10189302 | 0.82 | PTGS2 (0.40) | PTGS2DHFRKDM4EGAKHTT | |
| SCHEMBL10188948 | 0.81 | PTGS2 (0.41) | PTGS2KDM4EALDH1A1 | |
| SCHEMBL10188804 | 0.81 | PTGS2 (0.67) | PTGS2DYRK1A | |
| SCHEMBL10188879 | 0.80 | PTGS2 (0.48) | PTGS2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN (US) | 2013-08-08 | — | — | US | disclosed |
| US-8399435-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PTGS2 3488/4885DHFR 122/4885KDM4E 2492/4885 |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PTGS2 3488/4885DHFR 122/4885KDM4E 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.